Secondary mutations at I1171 in the ALK gene confer resistance to both crizotinib and alectinib

Journal of Thoracic Oncology

Volumn 9, Issue 12, 2014, Pages e86-e87

  Toyokawa, Gouji ^a   Hirai, Fumihiko ^a   Inamasu, Eiko ^a   Yoshida, Tsukihisa ^a   Nosaki, Kaname ^a   Takenaka, Tomoyoshi ^a   Yamaguchi, Masafumi ^a   Seto, Takashi ^a   Takenoyama, Mitsuhiro ^a   Ichinose, Yukito ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; CISPLATIN; CRIZOTINIB; NAVELBINE; PEMETREXED; ANAPLASTIC LYMPHOMA KINASE; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ALK GENE; BONE METASTASIS; BRAIN METASTASIS; CANCER RESISTANCE; CASE REPORT; CODON; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PLEURA EFFUSION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT SURVEY; SKIN BIOPSY; SKIN METASTASIS; TREATMENT RESPONSE; BONE NEOPLASMS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYMOLOGY; GENE FUSION; GENETICS; LUNG NEOPLASMS; MULTIDRUG RESISTANCE; MUTATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY;

ADULT; BONE NEOPLASMS; BRAIN NEOPLASMS; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE FUSION; HUMANS; LUNG NEOPLASMS; MUTATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84926421984     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000358     Document Type: Article

References (8)

1. Camidge DR, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol 2012;9:268-277.
2. Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4:662-673.
3. Choi YL, Soda M, Yamashita Y, et al; ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-1739.
4. Ignatius Ou SH, Azada M, Hsiang DJ, et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014;9:549-553.
5. Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 2014;351:215-221.
6. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679-690.
7. Zhang S, Wang F, Keats J, et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 2011;78:999-1005.
8. Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res 2013;11:122-132.